Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart
Vir Biotechnology announces positive EMA COMP opinion for orphan drug designation of tobevibart and elebsiran for chronic hepatitis delta, based on Phase 2 SOLSTICE trial data.
Vir Biotechnology Secures Key EU Orphan Drug Status for Hepatitis Delta Treatment
Vir Biotechnology receives positive opinion from EMA for orphan drug designation of tobevibart and elebsiran in treating chronic hepatitis delta, following FDA fast track designation in June 2024. The orphan designation could provide 10 years of market exclusivity in the EU upon approval.
Related Clinical Trials:
Vir Biotechnology (VIR) Gets a Buy from Barclays
Barclays analyst Gena Wang assigns a Buy rating to Vir Biotechnology with a $26.00 price target. Wang, a 4-star analyst with a 41.25% success rate, also covers BioMarin Pharmaceutical, Avidity Biosciences, and Alnylam Pharma. Vir Biotechnology received a Buy rating from H.C. Wainwright’s Patrick Trucchio and a Hold rating from Morgan Stanley. The company’s market cap is $1.1B with a P/E ratio of -2.04, and insider sentiment is negative due to increased insider selling.
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart
Vir Biotechnology announced end-of-treatment data from MARCH Phase 2 study evaluating tobevibart and elebsiran combinations for chronic hepatitis B, showing promising HBsAg loss rates in participants with low baseline HBsAg.
Promising Hepatitis B Treatment Data Amid Cautious Optimism and ...
Morgan Stanley's Michael Ulz maintains a Hold rating on Vir Biotechnology with a $10.00 price target, citing promising but mixed results from Hepatitis B treatment studies. Safety profiles remain positive, but overall efficacy varies, with crucial functional cure data expected by Q2 2025. J.P. Morgan also maintains a Hold rating with a $13.00 target.
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and ...
MARCH Phase 2 study shows 39% and 46% HBsAg loss in low baseline HBsAg participants with tobevibart + elebsiran and tobevibart + elebsiran + PEG-IFNα, respectively. No new safety concerns; TEAEs mild to moderate. Functional cure data expected Q2 2025.
Vir Biotechnology reports 'positive' end-of-treatment data from MARCH study
Vir Biotechnology announced promising hepatitis B surface antigen loss rates in MARCH Phase 2 study, supporting further development towards a functional cure. Data to be presented at AASLD on November 18.
© Copyright 2024. All Rights Reserved by MedPath